{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:57Z","timestamp":1790207757640,"version":"4.1.0"},"reference-count":106,"publisher":"Korean Liver Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-jlc.org"],"crossmark-restriction":true},"short-container-title":["JLC"],"published-print":{"date-parts":[[2024,9,30]]},"abstract":"<jats:p>Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone of advanced CCA treatment. More recently, immunotherapy has changed the therapeutic landscape, as immune checkpoint inhibitors have yielded the first improvement in survival and currently, the addition of either durvalumab or pembrolizumab to standard of care cisplatin plus gemcitabine represents the new first-line treatment option. However, the use of immunotherapy in subsequent lines has not demonstrated its efficacy and therefore, it is not approved, except for pembrolizumab in the selected microsatellite instability-high population. In addition, advances in comprehensive genomic profiling have led to the identification of targetable genetic alterations, such as isocitrate dehydrogenase 1 (IDH1), fibroblast growth factor receptor 2 (FGFR2), human epidermal growth factor receptor 2 (HER2), proto-oncogene B-Raf (BRAF), neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), Kirsten rat sarcoma virus (KRAS), and mouse double minute 2 homolog (MDM2), thus favoring the development of a precision medicine approach in previously treated patients. Despite these advances, the use of molecularly driven agents is limited to a subgroup of patients. This review aims to provide an overview of the newly approved systemic therapies, the ongoing studies, and future research challenges in advanced CCA management.<\/jats:p>","DOI":"10.17998\/jlc.2024.08.07","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T08:15:12Z","timestamp":1723104912000},"page":"155-170","update-policy":"https:\/\/doi.org\/10.17998\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["New systemic treatment options for advanced cholangiocarcinoma"],"prefix":"10.17998","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-6601","authenticated-orcid":true,"given":"Valentina","family":"Zanuso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-6585","authenticated-orcid":true,"given":"Giulia","family":"Tesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5006-9535","authenticated-orcid":true,"given":"Elena","family":"Valenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":true,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7328","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.157"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14095"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.022"},{"key":"ref5","first-page":"663","volume-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","author":"Primrose","year":"2019"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"ref7","first-page":"694","volume-title":"NCCN guidelines\u00ae insights: biliary tract cancers, version 2.2023","author":"Benson","year":"2023"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0908721"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605779"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt540"},{"key":"ref11","first-page":"1950","volume-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","author":"Morizane","year":"2019"},{"key":"ref12","first-page":"102","volume-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","author":"Ioka","year":"2023"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00679"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.4_suppl.lba490"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.4006"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00027-9"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.019"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00486-1"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.081"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31092"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.4079"},{"key":"ref22","first-page":"1","volume-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","author":"Marabelle","year":"2020"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.4588"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.4108"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00043-7"},{"key":"ref28","first-page":"EVIDoa2200015","volume-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","author":"Oh","year":"2022"},{"key":"ref29","first-page":"694","volume-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","author":"Oh","year":"2024"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00082-2"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15641"},{"key":"ref32","first-page":"359","volume-title":"Durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in biliary tract cancer: a real-world retrospective, multicenter study","author":"Rimini","year":"2024"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01044-1"},{"key":"ref34","first-page":"1853","volume-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Kelley","year":"2023"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.4093"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598877"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.4_suppl.491"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.3_suppl.435"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.3_suppl.321"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.03.007"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000564"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000365"},{"key":"ref45","first-page":"3575","volume-title":"MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer","author":"Yamamoto","year":"2005"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e3181fb65b9"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01342-6"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-011-0437-y"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0432"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.444"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.030"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32424"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00156"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00933-7"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(19)30189-x"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30157-1"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836"},{"key":"ref60","first-page":"S162","volume-title":"Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: phase 3 ClarIDHy trial","author":"Valle","year":"2023"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00197"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231171574"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00304-5"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113310"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-024707"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102170"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30109-1"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0429"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113587"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206834"},{"key":"ref72","first-page":"S163","volume-title":"Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study","author":"Hollebecque","year":"2023"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.4_suppl.tps600"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.3_suppl.tps572"},{"key":"ref75","first-page":"AB051","volume-title":"A phase II study of infigratinib (BGJ398) in previouslytreated advanced cholangiocarcinoma containing FGFR2 fusions","author":"Javle","year":"2019"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00196-5"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0299"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.3_suppl.516"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0334-0"},{"key":"ref80","first-page":"S567","volume-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications","author":"Borad","year":"2022"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.4117"},{"key":"ref82","first-page":"925","volume-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","author":"Pant","year":"2023"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.4009"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0766"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.3_suppl.434"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.3_suppl.473"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9645-x"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2020.08.006"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00336-3"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00335-1"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00621-0"},{"key":"ref92","first-page":"772","volume-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","author":"Harding","year":"2023"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.4006"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02005"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00606"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00402-2"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36399-y"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00385"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30691-6"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30856-3"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01931-y"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00541-1"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.36_suppl.425082"},{"key":"ref105","first-page":"487","volume-title":"Efficacy and safety of brigimadlin (BI 907828), an MDM2\u2013p53 antagonist, in patients (pts) with advanced biliary tract cancer: data from two phase Ia\/Ib dose-escalation\/expansion trials","author":"Macarulla","year":"2024"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.013"}],"container-title":["Journal of Liver Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-jlc.org\/upload\/pdf\/jlc-2024-08-07.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jlc.org\/journal\/view.php?doi=10.17998\/jlc.2024.08.07","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jlc.org\/upload\/pdf\/jlc-2024-08-07.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T07:02:37Z","timestamp":1727679757000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-jlc.org\/journal\/view.php?doi=10.17998\/jlc.2024.08.07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.17998\/jlc.2024.08.07","relation":{},"ISSN":["2288-8128","2383-5001"],"issn-type":[{"value":"2288-8128","type":"print"},{"value":"2383-5001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"2024-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}